

AD _____

GRANT NUMBER DAMD17-94-J-4045

TITLE: Defining the Smallest Common Region of Chromosome 17p
that is Deleted in Sporadic Breast Tumors

PRINCIPAL INVESTIGATOR: Max S. Wicha, M.D., Ph.D.
Sofia D. Merajver, M.D.

CONTRACTING ORGANIZATION: University of Michigan
Ann Arbor, Michigan 48109

REPORT DATE: October 1996

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19970226 117

DTIC QUALITY INSPECTED 1

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 1996	3. REPORT TYPE AND DATES COVERED Annual (1 Oct 95 - 30 Sep 96)	
4. TITLE AND SUBTITLE Defining the Smallest Common Region of Chromosome 17p that is Deleted in Sporadic Breast Tumors			5. FUNDING NUMBERS DAMD17-94-J-4045	
6. AUTHOR(S) Max S. Wicha, M.D., Ph.D. Sofia D. Merajver, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Michigan Ann Arbor, Michigan 48109-1274			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, MD 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) Germline mutations in breast cancer susceptibility genes account for 8% of all breast cancer cases. BCRA1 on 17q12 and BCRA2 on 13q12-13 are implicated in 50%-60% of breast cancer families, and they are both likely to also have an impact in sporadic breast cancer cases. Recently defined loci on chromosome 8p 12-22 are frequently lost in sporadic breast cancers and there is evidence for families with linkage to these loci. We propose to ascertain 8 ethnically diverse (non-Caucasian) families linked to putative BCRA3 loci on chromosome 8p, and to investigate whether a recently isolated prostate cancer metastases suppressor gene, KAI1, is involved in the genetic alterations of inflammatory breast cancer, a particularly aggressive form of breast cancer which accounts for 15% of all cases.				
14. SUBJECT TERMS Humans, Anatomical Samples, Tumor Suppressor Genes, Allelic Imbalance, Chromosome 17, Breast Cancer			15. NUMBER OF PAGES 6	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

SIOM For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

SIOM In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

SIOM In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

SIOM
PI - Signature

10/29/96
Date

Table of contents

Introduction.....	Page	2
Body.....	Page	3
Conclusions.....	Page	6
References.....	Page	6

Introduction

Hereditary breast cancer accounts for 5-8% of breast cancer cases (1). Loci on 8p12-22 are frequently lost in breast tumors and may thus harbor one or more tumor suppressor genes (2). Almost all of breast cancer families studied so far in North America and Western Europe are of Caucasian origin. *We hypothesize that more ethnically diverse families with evidence of autosomal dominant transmission of breast cancer are needed to study loci on 8p12-22.* As current data indicate that *BRCA2* families are rarer than previously predicted, *we hypothesize that a proportion of families found to be unlinked to both BRCA1 and BRCA2 will be linked to recently defined loci on chromosome 8p12-22; as a corollary, the characterization of the 8p-linked familial tumors will help define the limits of the candidate regions on this chromosome.* The specific aims proposed in this application are:

1. To ascertain at least 5 site-specific breast cancer families of diverse ethnic background who are linked to loci on chromosome 8p12-22.
2. To analyze the 8p-linked tumors for LOH at closely spaced markers to help refine the breast cancer candidate region(s).
3. To test families unlinked to *BRCA1*, *BRCA2*, and loci on 8p12-22 for linkage to the *KAI1* gene, a metastases suppressor gene, and to analyze sporadic breast tumors for mutations in *KAI1*.

SIGNIFICANCE AND PRELIMINARY STUDIES

Family collection.

Breast cancer will affect 1,600,000 women world-wide in 1995. In the US alone, 48,000 will die of this disease in 1996 (3). The discovery of breast cancer susceptibility genes has allowed the study of a relatively simple and unique model system for human mammary epithelial carcinogenesis. The tumors suffered by the women belonging to these families are clinically indistinguishable from sporadic tumors. Our laboratory has recently proven that at least 10% of sporadic ovarian cancers undergo inactivation of both *BRCA1* alleles.

The scarcity of African American and other minority families in the study of breast cancer susceptibility genes provides the impetus for this application which combines basic research in molecular genetics of breast cancer with a rational attempt at a minority family collection (5-8). The study of the etiology of the widening gap in survival (3) between Caucasian and African American populations requires that future experiments on cancer susceptibility genes be done on an ethnically balanced population of samples. *The lack of availability of these samples and the long lag-time for their acquisition have invariably been the limiting factors. Our proposal intends to contribute shared resources. The Breast Cancer Tissue Core at the University of Michigan (DOD-funded; S. Ethier, Principal Investigator; S. Merajver, co-investigator) provides an independently funded mechanism to freely share these resources for the next 4 years.*

Epidemiological data on family history and breast cancer incidence on Hispanic, Japanese, and Arab women suggests that familial clustering of breast cancer also appears in these populations (9-11). We have been involved for 5 years in an extensive breast cancer family collection and counseling which was at first dedicated to the positional cloning effort of the breast cancer susceptibility gene, *BRCA1* (12,13). *Since 7/1/94, under the direction of Dr. Sofia Merajver, the Breast Cancer Genetics Project has ascertained 114 new breast cancer families. Thirty of those families are in active collection, and 7 have been completely collected.* The principal sources of referrals are: the University of Michigan Breast Care Center (BCC) (450 new breast cancer patients a year), community surgeons, oncologists, and general practitioners; physicians at other research institutions. We have established a successful collaboration with researchers at Henry Ford Hospital (HFH) in Detroit, MI, where a large number (over 150/year) of African American and Hispanic breast cancer patients with a family history are diagnosed and treated. *The family collection at the University of Michigan has proven invaluable in the localization of BRCA1 and in the assessment of familial mutations. The collection provides a renewable source of RNA and DNA for functional studies after a tumor suppressor gene is cloned. The families ascertained through the research have the option of gaining knowledge of their risk if they so wish under approved protocols.*

Linkage studies to 8p12-22 and other loci.

Fueled by the observation in several laboratories that fewer (10-20%) breast cancer families than previously anticipated (40-50%) are linked to *BRCA2*, other candidate loci such as 8p12-22 are being actively tested, where LOH has consistently been observed above background levels. Forty-seven percent of tumor

samples have LOH here and at least one breast cancer family with a LOD (logarithm base 10 of the odds favoring linkage) score of 3.70 for markers in this locus has been described. The study of specific breast cancer families linked to the different loci will provide key information and materials for the understanding of these pathways. *The preliminary studies described here show that there is enough statistical evidence to pursue other tumor suppressor loci as putative familial cancer susceptibility genes on chromosomes 8p12-22 and 11p.*

Loss of heterozygosity (LOH)

Following Knudsen's "two-hit hypothesis" (19), loss of heterozygosity (LOH) is generally a marker of the presence of a tumor suppressor gene. S. Merajver has studied LOH in familial and sporadic breast and ovarian tumors for the last 4 years (4,12). *These experiments demonstrate that LOH at closely spaced, ordered markers on a tumor suppressor candidate region can define a minimum region of overlap and help localize the desired transcript. This experimental design can be extended to other tumor suppressor regions, such as 8p12-22.*

Mutation analyses of familial and sporadic specimens.

Advances in familial cancer syndromes are also relevant to sporadic carcinogenesis. For example, the PI and others have recently shown that *BRCA1* is implicated in sporadic carcinogenesis (4). Dr. Merajver's laboratory was the first to report 4 somatic mutations (12). The initial screen for mutations was performed by a modification of single-strand conformation polymorphism (SSCP) technique. *These experiments show that even for a fairly large gene such as BRCA1, thorough, semi-automated, batch-mode mutation analyses can be performed efficiently and rapidly with a combination of SSCP and direct sequencing of familial and sporadic tumors. Even in the complicated situation posed by BRCA1, these methods have proven effective; we believe that it is not overly optimistic to predict that they will serve us well for tumor suppressor genes on 8p12-22.*

SUMMARY OF PRELIMINARY STUDIES .

The PI has performed family collection studies (13), directs a high-risk breast cancer clinic where family members are counseled, has conducted detailed mapping studies of sporadic tumors by LOH (12), and has ascertained that the mutations of the first described familial breast cancer gene (*BRCA1*) are present in sporadic tumors (4). Research in all these areas has been published in the peer-reviewed literature. (4,12,13)

Body

The work performed in Dr. Merajver's laboratory under this grant is part of a multifaceted collaborative effort to understand the molecular genetics of familial and sporadic breast cancers. As can be seen below, we have proceeded with our studies of families with potential linkage to *BRCA3* putatively assigned to chromosomal region 8p12-22. In addition, the much welcomed isolation of the *BRCA2* gene in the period covered by this report provoked a transitory change in direction, due to the urgency and timeliness of ascertaining the role of *BRCA2* in sporadic tumors and the sequencing of the full length cDNA. Our laboratory collaborated in efforts towards solving these problems; peer-reviewed publications reporting findings on the *BRCA2* gene have already appeared, and more are being prepared at the time of this writing. In addition, the quest for understanding both the molecular genetics and the clinical course of familial and sporadic breast cancer has led to publications in the clinical breast cancer literature, supported in part by this grant. A complete list of publications which have appeared or are in press for the period 10/1/95-9/31/96, are listed at the end of this section.

The work on 8p involving families and tumors has progressed as follows, in accordance to the specific aims of the project.

Family ascertainment. We assembled an information network by obtaining the names and addresses of charitable organizations and predominantly minority (mainly African American and Hispanic) churches in the metropolitan Detroit area and by an ongoing collaboration with HFH. We will be sending a mailing outlining the project to these individuals and organizations in the next few weeks. We are seeking families with 3 or more cases of female breast cancer in 2 or more generations within a lineage, average age of onset < 60 years, bilateral disease, or male breast cancer. Because of our success in obtaining and using tumor blocks, we are not limited by the number of living affected individuals, as long as we are able to ascertain that the tumor blocks are indeed available. We expect to ascertain 3-4 8p12-22 families through the screening of new

minority cases at UM and HFH. The remaining 2-3 *BRCA2* families will be ascertained through the community-based effort we have begun with African American church leaders in the Detroit metropolitan area, which has a 40% minority population communication. We aim to complete the family ascertainment and analyses of pedigrees during the next 6 months even if the community-oriented efforts are only half as successful as our expectations. Of the 23 non-*BRCA1* non-*BRCA2* families we have screened so far, 4 have shown to share a common haplotype at 8p12-22, but the LOD scores are small due to the small number of affected individuals whose specimens are available. We are yet to fully utilize the community resources we have gathered, but we expect to accomplish that in the next 6 months, approximately as planned in the SOW.

Familial specimen collection.

The collection of blood specimens has been undertaken in the manner in which we have proceeded so far, under an IRB-approved protocol. In brief, after signing informed consent, we draw 3 lavender-top tubes (5 cc each) for DNA and 2 green-top tubes (for lymphocyte immortalization). The DNA extraction and immortalization protocols are described below. Pre-paid mailing kits or travel to the family's domicile are used for remote specimens. This latter method is very cost-effective, allows for the establishment of close rapport with the family, and provides for an opportunity to answer questions regarding the research and breast cancer. The familial specimen collection is proceeding at an extremely fast pace, with over 50 tumor specimens, many of them quite old and from remote sites, already received and processed at the University of Michigan. We have extracted the DNA and have started the LOH experiments on 8p. We are also poised to proceed in an expedient manner were the actual *BRCA3* gene to be isolated by other labs in the near future. This portion of aim 1 is ahead of schedule as per the SOW.

Linkage analyses.

Linkage analysis is performed using the method of LOD scores (14-16). Calculations are carried out with the programs MENDEL (15) and LINKAGE (16). All families will be screened for linkage to *BRCA1* with *D17S855* and *D17S1323*, two intragenic polymorphic markers, and *BRCA2*., the latter with *D13S221*, *D13S260*, *D13S267*, and *D13S263*. Following Kerangueven et al (2), we will use the following panel of markers on 8p12-22 (Table 1).

For each family not linked to either *BRCA1*, or *BRCA2*, or 8p12-22, rapid SSCP analyses of 2 affected individuals with age of onset of cancer under 50 will be conducted on the *KAI1* gene on 11p11.2 (17). The primers for this gene have been designed and synthesized, and tested on DNA from lymphocytes and archival materials. we are planning to proceed to "run" the *KAI1* gene through these tumors in the next 6-12 months.

TABLE 1. 8p markers to be used in this study ordered from centromere to telomere

Tumor LOH	Linkage studies
D8S137	D8S137
<i>NEFL</i>	<i>NEFL</i>
D8S259	
D8S133	D8S133
D8S258	
<i>LPL</i>	
D8S261	D8S261
D8S265	

The 8p markers have all been synthesized, tested on trial paraffin specimens (we are always extremely frugal with our valuable familial specimen resources), and optimized for amplification of paraffin-embedded material. The analyses of 50 familial and over 40 sporadic specimens along the 8p12-22 region will continue for the next 1.2 years, as per the SOW.

Additional Projects and Publications. (Completed under this grant due to auspicious circumstances which modified and expanded the course of the research).

BRCA2. Cloning and sequencing of the full-length cDNA, and analyses of mutations in families, as well as the investigation of the role of *BRCA2* in familial and sporadic male breast cancers.

Risk Assessment and Counseling. Outlining of important concepts for the physician and detailed description of risk assessment strategies in a breast/ovarian high-risk clinic.

Miscellaneous. The use of mammography in locally advanced breast cancer to determine which patients are amenable to breast conservation. Although seemingly unrelated, this work actually ties in beautifully with our work on the KAI1 gene, because it is these aggressive tumors which we are targeting for studying the KAI1 gene on.

List of Publications.

1. L. Pierce, D. Adler, M.A. Helvie, A. Lichter, S.D. Merajver, "The Use of Mammography in Breast Preservation in Locally Advanced Breast Cancer," *Int J Radiation Oncology Biol Phys* **34**:571-577 (1996).
2. S.D. Merajver and E. Petty, "Risk Assessment and Presymptomatic Molecular Diagnosis in Hereditary Breast Cancer," *Clinics in Laboratory Medicine (DNA Technology)* **16**:139-168 (1996).
3. RF Caduff, CM Johnston, SM Svoboda, EL Poy, SD Merajver, TS Frank: Clinical and pathologic significance of microsatellite instability in sporadic endometrial carcinoma. *Am J Pathol* **148** (5):1671-8, 1996.
4. M.A. Helvie, L.K. Joynt, R.L. Cody, L.J. Pierce, D.D. Adler, S. D. Merajver, "Locally Advanced Breast Carcinoma: Accuracy of Mammography versus Clinical Examination in the Prediction of Residual Disease after Chemotherapy," *Radiology* **198**:327-332 (1996).
5. K.A. Cooney, J.C. Wetzel, S.D. Merajver, J.A. Macoska, T.P. Singleton, K.J. Wojno, "Disting Regions of Allelic Loss on 13q in Prostate Cancer," *Cancer Research* **56**:1142-1145 (1996).
6. S.V. Tavtigian, J. Simard, J. Rommens, F. Couch, D. Shattuck-Eidens, S. Neuhausen, S.D., Merajver, et al., "The BRCA2 Gene and Mutations in 13q-Linked Kindreds," *Nature Genetics* **12**:333-337 (1996).
7. L. Pierce, D. Adler, M.A. Helvie, A. Lichter, S.D. Merajver, "The Use of Mammography in Breast Preservation in Locally Advanced Breast Cancer," *Int J Radiation Oncology Biol Phys* **34**:571-577 (1996).
8. S.D. Merajver and E. Petty, "Risk Assessment and Presymptomatic Molecular Diagnosis in Hereditary Breast Cancer," *Clinics in Laboratory Medicine (DNA Technology)* **16**:139-168 (1996).
9. F.J. Couch, L.M. Farid, M.L. DeShano, S.V. Tavtigian, K. Calzone, L. Campeau, Y. Peng, B. Bogden, Q. Chen, S. Neuhausen, D. Shattuck-Eidens, A.K. Godwin, M. Daly, D.M. Radford, S. Sedlacek, J. Rommens, J. Simard, J. Garber, S.D. Merajver, B.L. Weber, "BRCA2 germline mutations in male breast cancer cases and breast cancer families," *Nature Genetics* **13**:123-125 (1996).
10. J.S. Simon, G. Deshmukh, F.J. Couch, S.D. Merajver, B.L. Weber, P. VanVooren, F. Tissil, J. Szpirer, C. Szpirer, S.L. Alper, H.J. Jacob, F.C. Brossius, III, "Chromosomal Mapping of the Rat Slc4a Family of Anion Exchanger Genes, Ae1, Ae2, and Ae3," *Mammal Genome* **7**:380-382 (1996).
11. R.F. Caduff, C.M. Johnston, S.M. Svoboda, E.L. Poy, S.D. Merajver, and T.S. Frank, "Clinical and Pathologic Significance of Microsatellite Instability in Sporadic Endometrial Carcinoma," *Am J Pathol* **148** (5):1671-8, 1996.

12. K.J. Abel, L.C. Brody, J.M. Valdes, M.R. Erdos, D.R. McKinley, L.H. Castilla, S.D. Merajver, et al.: Characterization of EZH1, a human homolog of *Drosophila Enhancer of zeste* near BRCA1. Genomics (In Press).

Conclusions

It is still premature to draw definitive conclusions from the research described above, except in those cases where the material has already been published. Our preliminary work on 8p encourages us even more than when the grant was written, to aggressively pursue this line of research, as we expect this region will be crucial in our understanding of breast carcinogenesis.

References

1. Shattuck-Eidens D, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. JAMA 273:535-541 (1995).
2. Kerangueven F, et al. Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8. Oncogene 10:1023-1026 (1995).
3. American Cancer Society: Cancer Statistics, CA 45:1-20 (1995).
4. Merajver SD, et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature (Genetics) 9:439-443 (1995).
5. Amos CI, Goldstein AM, Harris EL. Familiality of breast cancer and socioeconomic status in blacks. Cancer Res. 51:1793-7 (1991).
6. Schatzkin A, Palmer JR, Rosenberg L, Helmrich SP, Miller DR, Kaufman DW, Lesko SM, Shapiro S. Risk factors for breast cancer in black women. J Natl Cancer Inst. 78:213-7 (1987).
7. Bondy ML, Fueger JJ, Vogel VG, Spitz MR. Ethnic differences in familial breast cancer. Proc Annu Meet Am Assoc Cancer Res. 32:A1316 (1991).
8. Siraganian PA, Levine PH, Madigan P, Mulvihill JJ. Familial breast cancer in black Americans. Cancer 60:1657-60 (1991).
9. Weiss KM, et al. Familial aggregation of cancer in Laredo, Texas: a generally low-risk Mexican-American population. Genet Epidemiol 3:121-43 (1986).
10. Kato I, et al. A case-control study of breast cancer among Japanese women: with special reference to family history and reproductive and dietary factors. Breast Cancer Res. Treat 24:51-9 (1992).
11. Zidan J, Diab M, Robinson E. Familial breast cancer in Arabs. Harefuah 122:767-9, (1992).
12. Merajver SD, et al. Germline *BRCA1* mutations and loss of the wild-type allele in tumors from families with early-onset breast ovarian cancer. Clin. Cancer Research 1:539-544 (1995).
13. Hoskins KF, et al. Assessment and counseling for women with a family history of breast cancer: a guide for clinicians. JAMA 273:577-585 (1995).
14. Morton NE. Sequential tests for the detection of linkage. Am J Hum Genet 7:277-318 (1955).
15. Lange K, Weeks D, Boehnke M. Programs for pedigree analysis: MENDEL, FISHER and dGENE. Genet Epidemiol 5:471-472 (1988).
16. Lathrop GM, Lalouel J-M. Efficient computations in multilocus linkage analysis. Am J Hum Genet 42:498-505 (1984).
17. Dong J-T, et al. *KAI1*, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268:884-886 (1995).
18. Castilla LH et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nature (Genetics) 8:387-91(1994).
19. Knudson AG. Antioncogenes and human cancer. Proc Nat Acad Sci USA 90:10914-10921(1993).